217 related articles for article (PubMed ID: 29157828)
1. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
[TBL] [Abstract][Full Text] [Related]
2. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
[TBL] [Abstract][Full Text] [Related]
3. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.
Schad F; Axtner J; Kröz M; Matthes H; Steele ML
Integr Cancer Ther; 2018 Mar; 17(1):41-51. PubMed ID: 29444603
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
[TBL] [Abstract][Full Text] [Related]
5. Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters.
Kienle GS; Grugel R; Kiene H
BMC Complement Altern Med; 2011 Aug; 11():72. PubMed ID: 21871125
[TBL] [Abstract][Full Text] [Related]
6. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer.
Thronicke A; Steele ML; Grah C; Matthes B; Schad F
BMC Complement Altern Med; 2017 Dec; 17(1):534. PubMed ID: 29237435
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
8. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Evid Based Complement Alternat Med; 2014; 2014():724258. PubMed ID: 24672577
[TBL] [Abstract][Full Text] [Related]
9. Viscum album L. Therapy in Oncology: An Update on Current Evidence.
Thronicke A; Schad F; Debus M; Grabowski J; Soldner G
Complement Med Res; 2022; 29(4):362-368. PubMed ID: 35325897
[TBL] [Abstract][Full Text] [Related]
10. Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Evid Based Complement Alternat Med; 2014; 2014():236310. PubMed ID: 24955100
[TBL] [Abstract][Full Text] [Related]
11. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer.
Axtner J; Steele M; Kröz M; Spahn G; Matthes H; Schad F
BMC Cancer; 2016 Aug; 16():579. PubMed ID: 27485618
[TBL] [Abstract][Full Text] [Related]
12. Use and Safety of Viscum album L Applications in Cancer Patients With Preexisting Autoimmune Diseases: Findings From the Network Oncology Study.
Oei SL; Thronicke A; Kröz M; Matthes H; Schad F
Integr Cancer Ther; 2019; 18():1534735419832367. PubMed ID: 30808274
[TBL] [Abstract][Full Text] [Related]
13. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.
Schad F; Thronicke A; Steele ML; Merkle A; Matthes B; Grah C; Matthes H
PLoS One; 2018; 13(8):e0203058. PubMed ID: 30148853
[TBL] [Abstract][Full Text] [Related]
14. Local reactions to treatments with Viscum album L. extracts and their association with T-lymphocyte subsets and quality of life.
Büssing A; Tröger W; Stumpf C; Schietzel M
Anticancer Res; 2008; 28(3B):1893-7. PubMed ID: 18630477
[TBL] [Abstract][Full Text] [Related]
15. High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series.
von Schoen-Angerer T; Wilkens J; Kienle GS; Kiene H; Vagedes J
Perm J; 2015; 19(4):76-83. PubMed ID: 26517439
[TBL] [Abstract][Full Text] [Related]
16. [Viscum album L. (Iscador) in the cat: tolerance, adverse reactions and indications].
Glardon ; Pache ; Magnenat ; Pin ; Parvis
Schweiz Arch Tierheilkd; 2014 Aug; 156(8):381-8. PubMed ID: 25082635
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Schad F; Atxner J; Buchwald D; Happe A; Popp S; Kröz M; Matthes H
Integr Cancer Ther; 2014 Jul; 13(4):332-40. PubMed ID: 24363283
[TBL] [Abstract][Full Text] [Related]
18. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
[TBL] [Abstract][Full Text] [Related]
19. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.
Huber R; Schlodder D; Effertz C; Rieger S; Tröger W
BMC Complement Altern Med; 2017 Sep; 17(1):465. PubMed ID: 28923036
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Cancer Biotherapy by Viscum Album Extract Isorel: Overview of Evidence Based Medicine Findings.
Sunjic SB; Gasparovic AC; Vukovic T; Weiss T; Weiss ES; Soldo I; Djakovic N; Zarkovic T; Zarkovic N
Coll Antropol; 2015 Sep; 39(3):701-8. PubMed ID: 26898069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
